In a significant advance in the field of ophthalmology, researchers at Harvard University have developed an innovative genetic treatment for age-related macular degeneration (AMD). This treatment, which uses a combination of gene therapy and CRISPR genome editing, has shown promising results in preclinical studies, significantly improving vision in animal models. Scientists hope that these findings can be translated into human clinical trials in the coming years, offering new hope for millions of people affected by this degenerative disease.